February 1, 2015
In North America and Europe approximately 940 million people are at risk of bioterrorism agents. According to the World Health Organization, its committee of experts’ estimates that an aircraft release of 50 kg of anthrax spores over an urban developed population of 5 million would result in about 250,000 deaths and an additional 125,000 would be severely incapacitated.
To protect major population centers, it will therefore be necessary to provide anthrax vaccines to a large segment of the population. In the US alone, billions of dollars have been budgeted for medical countermeasures to terrorism agents and to stockpile anthrax vaccines for a “three-city attack”. The problem with the presently available anthrax vaccine is its low immunogenicity. Several booster injections are required over a one-year period to establish immunity.
Greffex produced the anthrax vaccine GreANX based on its GreVAX Universal Platform. This anthrax vaccine has successfully undergone preclinical testing.
Another infectious agent with a bioterror threat potential similar to anthrax, is the plague. Greffex has been constructing the GrePla candidate vaccine as a single target vaccine that can be combined with GreANX for immunization. In parallel, Greffex has assembled GreVAX-based vaccine, GreAnPla, that carries antigens for anthrax and plaque on a single construct. This approach allows increased efficiency in manufacture and vaccination.
January 9, 2015
In studies sponsored by the National Institute of Allergy and Infectious Disease (NIAID), Greffex’s GreFluVie vaccine proved to be highly effective in protecting animals against H5N1. Mice were immunized in a prime/boost schedule before being challenged with a lethal dose of the pandemic avian influenza virus. At the low dose of 3×108 genome equivalents, the vaccine proved to be highly effective when given by intramuscular, subcutaneous, and intranasal routes. Intramuscular injection resulted in a rate of survival of 100%.
September 4, 2014
In the summer of 2014, Greffex was asked by the National Institute of Allergy and Infectious Diseases (NIAID) for a sample of its vaccine for MERS-CoV so that it could run tests to evaluate the production of neutralizing antibodies.
On a very tight schedule (less than two months) Greffex produced, purified, and vaccinated animals with the GreMERSfi. Mice were immunized in a prime/boost schedule with a small dose (approx. 3×108 genome equivalents). A standard micro-neutralization assay was used to quantify the humoral immune responses. All of the animals raised significant levels of neutralizing antibodies. 75% of the animals presented with very high antibody titers in the range of 640 to more than 2,560 (the test limit). In light of these results, the NIAID has invited Greffex to request further trials under its sponsorship.
AURORA, Colorado, June 24, 2013
MERS-CoV: In one month Greffex builds an advanced vaccine against the Middle East Respiratory Syndrome coronavirus
A scant two months after creating the first comprehensive vaccine for H7N9 avian influenza, Greffex developed a vaccine to protect against the Middle East Respiratory Syndrome coronavirus (MERS-CoV.) The vaccine was readied in just four weeks after MERS-CoV had moved to the WHO’s “alert phase” that also includes the human bird flu viruses H5N1 and H7N9.
platform combines a flexible ‘plug-and-play’TM
design accommodating different antigens, such as the MERS-CoV major surface S protein gene, with shortened development times of less than one month.
For more information about Greffex and its GREVAXTM vaccines, please go to our website: www.greffex.com or contact John R. Price at email@example.com / 303-577-0400.
AURORA, Colorado, 5/1/13
BusinessWire | Greffex has completed the construction of the first comprehensive vaccine against the virulent strain of H7N9 avian influenza.
Greffex scientists have created the first comprehensive vaccine for H7N9 avian influenza.
For more information about the Greffex and its GREVAXTM vaccines, please go to our website: www.greffex.com or contact John R. Price at firstname.lastname@example.org / 303-577-0400.